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The ACTI-I/MS&,, melanocortin core peptide sequence possesses neurotrophic properties in peripheral nerve. During functional neuroanatomical 
recovery after damage to peripheral nerves, Schwann cells play a significant role in facilitating regeneration. Here we employ a modified super-potent 
cz-MSH analogue to solubilise cc-MSH receptor proteins from cultured primary rat Schwann cells. [‘Z51-Ty?,Nle4,D-Phe7,ATB-Lys”]-&-MSH 
photoaffinity labelled proteins from Schwamr cells were analyzed by SDS-PAGE followed by autoradiography. The results indicate that the a-MSH 
receptor proteins labelled have a molecular weight of 4245 kDa. These data are the first to demonstrate solubilisation and characterisation of 
a-MSH receptors from non-melanoma cells. 
a-Melanocyte stimulating hormone; Receptor isolation; Melanocortin; Schwann cell; Nerve regeneration 
1. INTRODUCTION 2. MATERIALS AND METHODS 
a-Melanocyte stimulating hormone (a-MSH) (Ac- 
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-TrpGly-Lys-Pro-Val- 
NH,), has a multitude of well-recognised in vivo ac- 
tions, both in the peripheral [1,2] and the central [3] 
nervous systems. Its mechanism of action is thought to 
be receptor mediated [4,5], resulting, in melanoma cell 
lines and melanocytes in the elevation of intracellular 
concentrations of cyclic-AMP [68], the activation of 
protein kinase C [9] and the elevation of intracellular 
calcium [lo]. Stimulation of these cells by melanocortin 
peptides results in the activation of tyrosine kinases and 
the subsequent production of melanin. 
After nerve injury, caused by chemical [l 11, diabetic 
[12] or mechanical [131 trauma, a-MSH and its metabol- 
ically stable a-MSH, analogue 0rg2766 (Met(O,)- 
Glu-His-Phe-n-Lys-Phe-OH) can enhance functional 
regeneration of the nerve [14]. The characterisation of 
an 0rg2766 binding site on Schwann cells in vitro [15] 
has indicated that the Schwann cell may be a site for the 
neurotrophic actions of melanocortin-derived peptides. 
In this report we describe the isolation and partial 
characterisation of a plasma membrane-associated re- 
ceptor protein for a-MSH on primary rat Schwann cells 
by photoaffinity labelling using a monoiodinated pho- 
toreactive analogue of a-MSH, [Nle4,0-Phe7]a-MSH, a
technique which has successfully employed to identify 
c+MSH binding proteins on various melanoma cell lines 
[16,17]. 
*Corresponding author. 
All protease inhibitors were from Boehringer Mannheim. Enzymes 
for tissue dissociation were obtained from Sigma and DMEM from 
Northumbria Biologicals. [‘251-Ty?,Nle4,0-Phe’,ATB-Lysi’]-a-MSH 
was synthesized and iodinated as described previously [18]. 
2.1. Tissue culture 
Schwann cell cultures were obtained from the sciatic nerves of 
I-2-day-old Wistar-type rats of both sexes, according to the method 
of Brockes et al. [19], with modifications [15]. Briefly, the sciatic nerves 
were dissected out, pooled in cold, sterile PBS and finely minced (1 mm 
lengths). The tissue was then enzymically dissociated by treatment 
with Collagenase-type III (0.0546, 5 min, 37°C) followed by trypsin 
(0.25%, 15 min, 37’C). Collagenase was removed by low speed centrif- 
ugation and trypsin activity inhibited by the addition of FBS. Tissue 
was then dissociated mechanically by passage through 22- and 23- 
gauge needles. 
After pelleting cells were resuspended in high glucose (4500 mg/l) 
Dulbecco’s Modified Eagles’ Medium, supplemented with 10% FBS, 
2 mM glutamate, 25,000 U/ml penicillin and 25 mg/ml streptomycin. 
The presence of rapidly dividing contaminating fibroblasts was re- 
duced by the addition of cytosine j?-o-arabinofuranoside, ata concen- 
tration of 10 PM, 24 h after plating for 48-72 h. 
2.2. PhotoafJinity labelling and preparation of membranes 
Primary rat Schwann cells were grown on Ezin tissue culture flasks 
(175 cm*; Flow) to count of approximately 2x lo6 cells per flask, at 
37°C in a humidified atmosphere of 5% COJ95k air. Growth medium 
was removed and the cell were then incubated with [‘251-Ty?,Nle4,0- 
Phe’,ATB-Lys”]-a-MSH (0.1 nM) in binding buffer (DMEM; 25 mM 
HEPES, 0.2% (w/v) BSA and 0.3 mM l,lO-phenanthroline) in the 
presence or absence of 100 nM we4,0-Phe’]a-MSH. After 4 h incuba- 
tion at 4’C in the dark, the upper surface of the flask was peeled off 
and the cells were irradiated, on ice, with UV light of 320 nm (2 x 15 
W fluorescent ubes, FL1 5E UV-320) at a distance of about 10 cm for 
5 min. After irradiation the cells were scraped from the flask and 
washed by low-speed centrifugation (700 x g) to remove unbound 
ligand. The cells were resuspended in homogenisation buffer (10 mM 
Tris-HCl, pH 7.4, 0.3 mM l,lO-phenanthroline, 1 mM phenylmeth- 
Published by Elsevier Science Publishers B. V 103 
Volume 336, number 1 FEBSLETIERS December 1993 
ylsulphonylfluoride). They were kept on ice for 30 min and homogen- 
ised by five passages through a 21-gauge needle and five passages 
through a 25-gauge needle. The homogenate was centrifuged at 
20,000 x g for 30 min, at 4’C, to obtain crude membrane fractions. 
The pellet was resuspended in solubilisation buffer (10 mM Tris-HCl, 
pH 7.4, 5 mM EDTA, 1.5% (v/v) Triton X-100 and protein inhibitors 
at 0.1 &ml) and kept on ice for 1 h. The crude membrane fraction 
was then centrifuged at 50,000 x g for 1 h, at 4°C to obtain purified 
membrane fractions. 
2.3. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Purified membrane fractions were solubilised and SDS-PAGE was 
performed according to the method of Laemmli [20], using homogene- 
ous slab gels (20 x 16 cm, 1 mm thick) containing 10% acrylamide in 
the separating el. Following electrophoresis the gels were stained with 
Coomassie blue, dried and exposed on pre-flashed X-ray films with 
intensifying screens, at -70°C for 1 week. 
The apparent molecular weights of the labelled proteins were esti- 
mated by a graphical method in which the molecular weights of a series 
of ‘Wabelled protein standards were plotted against their relative 
mobilities. The standards used were myosin (200 kDa), phosphorylase 
B (97.5 kDa), BSA (69 kDa), ovalbumin (46 kDa), carbonic anhydrase 
(30 kDa) and lysozyme (14.3 kDa). 
2.4. Analysis of SDS-PAGE autoradiographs 
Autoradiographs were quantified by scanning on a BioRad GS-670 
imaging densitometer and the scan results for receptor labelling in the 
absence or presence of excess wle4-o-Phe’]-a-MSH from 30 kDa to 
200 kDa molecular weight proteins analysed in the BioRad Molecular 
Analyst software. 
3. RESULTS 
These experiments were performed using [lzsI-Ty?, 
Nle4,D-Phe7,ATB-Lys”]-a-MSH, a monoiodinated pho- 
toreactive a-MSH derivative. It has previously been 
demonstrated that this compound binds specifically to 
B16 melanoma cells [18]. Photoaffinity labelling was 
performed in the presence and absence of a large excess 
(100 nM) of unlabelled peptide to demonstrate the spec- 
ificity of binding. 
Incubation of primary rat Schwann cells with this 
monoiodinated photoreactive probe, followed by W 
irradiation, SDS-PAGE, autoradiography and den- 
sitometric analysis demonstrates the specific radioactiv- 
ity was localised in an apparent doublet protein band 
corresponding to molecular weight of 42-4.5 kDa pho- 
toaffinity labelled proteins (Fig. 1). A small amount of 
radioactivity was also observed at a higher and lower 
molecular weights, corresponding to 69 kDa and 
29 kDa. The presence of excess unlabelled [Nle4,0- 
Phe7]a-MSH completely removed the 42-45 kDa pro- 
tein doublet, but did not affect these other bands, indi- 
cating that the doublet represents pecific labelling of an 
a-MSH receptor or subunits of an a-MSH receptor 
complex, the other radiolabelled bands being proteins 
which bind a-MSH non-specifically. The signal gener- 
ated in Fig. 1 was associated with protein isolated from 
approximately 6 x lo7 cells. 
Densitometric analysis of the gel autoradiograph re- 
vealed a difference in ligand radioactive signal density 
104 
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Fig. 1. Autoradiography of SDS-PAGE treated [‘Z51-Tyr2,Nle4,0- 
Phe’,ATB-Lys”]-a-MSH labelled Schwann cell membrane proteins. 
(Lane a) W-labelled molecular weight markers; (lane b) membranes 
labelled with [‘251-Ty?,Nle4,0-Phe7,ATB-Lys”]-cl-MSH; (lane c) mem- 
branes labelled in the presence of excess cold unlabelled [Nle4,D-Phe’]- 
a-MSH. 
(Fig. 2), between membrane preparations that have 
been exposed to the photoreactive ligand in the presence 
and absence of excess me4,0-Phe7]a-MSH, that is in 
agreement with the low signal observed in the gel 
autoradiograph. 
4. DISCUSSION 
In this paper we report the first isolation and partial 
characterisation of a-MSH receptor proteins from cells 
of non-melanocyte origin emploing a novel ligand. 
Rat Schwann cell [1251-Tyr2,Nle4,b-Phe7,ATB-Lys11]-& 
MSH photoaffinity labelled proteins were isolated and 
analysed by SDS-PAGE followed by quantitative au- 
toradiography in order to determine the molecular 
weight of the a-MSH receptor. 
The results indicate that the proteins isolated have a 
molecular weight of 42-45 kDa. The abolition of these 
bands by incubation in the presence of excess unlabelled 
peptide indicates that this labelling was specific. Other 
bands, of higher (and one lower) molecular weights are 
also labelled. Labelling is reduced by the presence of 
excess unlabelled ligand, but is not wholly abolished. 
These non-specific bands cannot be identified at this 
stage. 
The band observed may or my not be a true doublet, 
whether caused by differences in the primary structure 
of the protein or the result of post-translational modifi- 
cations of the protein, or a solubilisation-induced arti- 
fact, remains to be established. However, preliminary 
studies on the receptor isolated from B16 melanoma 
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Fig. 2. Densitometric analysis of SDS-PAGE Autoradiograph. (a) Non-specific binding. (b) Specific labelling of doublet. Scans aligned with centres 
of 46 kDa marker. Proteins of interest arrowed. 
cells [18] indicates the receptor may exist in different 
states of N-glycosylation, with a core protein having an 
apparent molecular weight of 28 kDa [21], observed as 
a single band after SDS-PAGE. 
[‘*‘I]Naps-MSH labelling of B16 cells [18] revealed a 
labelled protein of 45 kDa, with a core weight of 42 kDa 
after neuramidinase treatment. This labelling was spe- 
cific, as controls of incubation in the presence of 3,000- 
fold excess a-MSH or Naps-MSH, the incubation of 
[‘*‘I]Naps-MSH in the dark, without UV irradiation or 
with UV photolysis of the ligand prior to the experiment 
proved to be negative. The Cloudman S91 cell line also 
bound the photolabelled ligand, but expressed a recep- 
tor protein with an apparent molecular weight of 
50 kDa, i.e. slightly larger than that on B16 cells, possi- 
bly due to a different glycosylation state. 
Receptors for melanocortin-derived peptides have 
also been identified previously on amphibian mela- 
nocytes in skin preparations [22], in the mammalian 
brain [23] and on primary cultures of rat Schwann cells 
[15] and neurones [24] in binding studies using a variety 
of radio- or biotin-labelled ligands. In all these studies 
isolation of the receptor protein(s) and their biochemi- 
cal characterisation has not been reported. 
Pharmacological binding and functional assays 
[14,22,23,25], however, have indicated that multiple 
melanocortin receptor types may exist. This has been 
supported with the recent cloning of the gene and ex- 
pression of the protein for melanocortin-derived pep- 
tide receptors [2628] and the characterisation of four 
sub-types of the melanocortin receptor. The four recep- 
tors have distinct profiles of pharmacological activity, 
though all are common in their membership of the G- 
protein coupled family of receptors. The melanocortin 
(MC)-1 receptor, which is the a-MSH receptor, is ex- 
pressed in melanocytes and melanoma tissues, the 
adrenocorticotrophin (ACTH) preferring MC-2 recep- 
tor has been localised to the adrenal cortex [26]. More 
recently the MC-3 and MC-4 receptors [27,28] have 
been localised to the hypothalamus (but not in mela- 
noma cells) and other regions of the brain associated 
with behavioural effects of the melanocortin peptides 
[3]. The MC-3 receptor has a requirement for an ACTH/ 
MSH core sequence, namely Met4-Glu/Gly-His-Phe- 
Lys-Trp-Gly/Aspi”, to be present in its ligands for bind- 
ing and biological activity. This requirement is similar 
to that seen previously in primary culture of rat 
Schwann cells [ 151 where Met(02)4-Glu-His is required 
for binding. The MC-4 sub-class also requires such a 
core sequence, however, there is an additional require- 
ment for Tyti for binding, and Pro’* for full biological 
activity. Due to the localisation of this protein, almost 
exclusively within the hippocampus [28] (the MC-3 re- 
ceptor is found in extra-hippocampal nervous tissues 
also) the MC-3 receptor is likely to be responsible in the 
mediation of behavioural responses by the classical pro- 
opiomelanocortin-derived peptides. 
Binding analysis with the superpotent ligand and re- 
ceptor number determination on Schwann cells was not 
possible, due to the low numbers of receptors on the 
105 
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cultured cells. In light the of the low signal generated in 
the autoradiograph the lack of this data is not surpris- 
ing. The development of an immortalised Schwann cell 
line that expresses this receptor and a more sensitive 
assay procedure for this cell type will be required to 
elucidate this data. 
We postulate that the receptor isolated and partially 
characterised from primary rat Schwann cells, as a 
42-45 kDa protein doublet similar to that of the B16 
melanoma cell line, is likely to be of the MC-l subclass 
of the meianocortin receptor family and not of the 
MC-2, -3 or -4 subclasses. 
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